Canadian Pegvisomant Compassionate Study In Acromegalic Patients

Back to Search
Print
Bookmark Trial

NCT00151437

Last updated date
Back to Search
Print
Bookmark Trial
FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Edmonton, Alberta, T6G 2B7, Canada
See other locations
Contact
1-800-718-1021
[email protected]
Related Links

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Acromegaly
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Subjects must have participated and completed the previous Pegvisomant studies or have shown to be unresponsive to other conventional therapies

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- ALT/AST>3 times the ULN or have hepatic disease


- have severe visual field loss, cranial nerve palsies or intracranial HTN that requires
surgery to decompress the tumor


- unwilling to self-administer the medication.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

Call Now

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Advanced Search

Based on your search, you may also be interested in

AcromegalyCanadian Pegvisomant Compassionate Study In Acromegalic Patients
NCT00151437
  1. Edmonton, Alberta
  2. Edmonton, Alberta
  3. Halifax, Nova Scotia
  4. Toronto, Ontario
  5. Montreal, Quebec
ALL GENDERS
18 Years+
years
MULTIPLE SITES
AcromegalyLong Term Use of Somavert (Pegvisomant) For A Regulatory Post Marketing Commitment Plan
NCT00658879
ALL GENDERS
0+
years
MULTIPLE SITES
AcromegalyLong Term Study With B2036-PEG
NCT00143416
  1. Kobe City, Hyogo Pref
  2. Kozukue-cho, Kouhoku-ku, Yokohama-shi, Kanagawa
  3. Hamamatsu-shi, Shizuoka-ken
  4. Bonkyo-ku, Tokyo
  5. Shinjuku-ku, Tokyo
  6. Gakuhara, Kishiwada, Osaka,
  7. Kyoto,
  8. Sannomaru-cho, Naka-ku, Nagoya-shi,
ALL GENDERS
20 Years+
years
MULTIPLE SITES
AcromegalyPegvisomant And Sandostatin LAR Combination Study
NCT00068029
  1. Los Angeles, California
  2. Boston, Massachusetts
  3. Chapel Hill, North Carolina
  4. Charlottesville, Virginia
  5. Darlinghurst, New South Wales
  6. Fitzroy, Victoria
  7. Fizroy, Victoria
  8. Rio de Janeiro, RJ
  9. São Paulo, SP
  10. Halifax, Nova Scotia
  11. Halifax, Nova Scotia
  12. Toronto, Ontario
  13. Montpellier Cedex,
  14. Nice Cedex,
  15. Berlin,
  16. Dresden,
  17. Hannover,
  18. Genova,
  19. Messina,
  20. Milano,
  21. Torino,
  22. Mexico, DF
  23. Col La Raza, Mexico Df
  24. Nijmegen,
  25. Oslo,
  26. Hospitalet de Llobregat, Barcelona
  27. Madrid,
  28. Belfast, Antrim
  29. Leeds,
  30. London,
  31. London,
  32. Manchester,
  33. Oxford,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Canadian Pegvisomant Compassionate Study In Acromegalic Patients
Official Title  ICMJE A Multi-Center, Open-Label Study For The Compassionate Use Of Pegvisomant In Acromegalic Patients Refractory To Conventional Therapy and For Patients Who Received The Product During The Clinical Development Program.
Brief Summary The purposes of this study are: 1) to provide SOMAVERT for compassionate use to patients with acromegaly or who have completed clinical trials and were responsive, and 2) to evaluate the safety and tolerability of SOMAVERT.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 4
Study Design  ICMJE Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Acromegaly
Intervention  ICMJE
  • Drug: Pegvisomant treatment
  • Procedure: Medical History, demographics
  • Procedure: Sign and symptoms: questionnaire
  • Procedure: Blood tests: IGF-1, AST/ALT/ALP/TBIL, GTT
  • Procedure: MRI
Study Arms  ICMJE Not Provided
Publications * Ezzat S, Gaspo R, Serri O, Ur E, Chik CL. A Canadian multi-centre, open-label long-term study of Pegvisomant treatment in refractory acromegaly. Clin Invest Med. 2009 Dec 1;32(6):E265.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Enrollment  ICMJE
 (submitted: September 7, 2005)		30
Original Enrollment  ICMJE Same as current
Actual Study Completion Date  ICMJE April 2007
Primary Completion Date Not Provided
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Subjects must have participated and completed the previous Pegvisomant studies or have shown to be unresponsive to other conventional therapies

Exclusion Criteria:

  • ALT/AST>3 times the ULN or have hepatic disease
  • have severe visual field loss, cranial nerve palsies or intracranial HTN that requires surgery to decompress the tumor
  • unwilling to self-administer the medication.
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Canada
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00151437
Other Study ID Numbers  ICMJE A6291017
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Not Provided
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date April 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP